Here at CLR we would have thought it would be very ethical.
We’d much rather debate ethics after a dose of THC than Asprin.
But, as they say, go figure
The British have seen many roadblocks on the way to cannabis reform. This is not just when it comes to recreational cannabis. Despite the legalization of the CBD market earlier this month, high THC cannabis remains a political third rail – especially when used for chronic pain.
A recent trial to treat this condition with cannabis, launched by a private Harley Street clinic, has just been dramatically scaled back after it failed to gain the approval of a needed ethics panel.
The plan had been to enroll up to 5,000 patients and allow them to use a tamper-proof inhaler (at a cost of about $350 per month) to consume whole-plant cannabinoids, including THC. After that, the goal was to encourage the National Health Service (or NHS) to finally cover medical cannabis costs for patients suffering from chronic pain.
So far, while it is possible to obtain high THC cannabis in the UK for medical purposes, it is impossible to receive reimbursement for chronic pain – which the government explicitly excluded from coverage.